This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance.
The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.
Age 18+
Signed CI for study partecipation and personal data processing.
Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM)
None
Study participants will be adult patients with monoclonal gammopathies, NDMM, RMM, and RRMM. Basing on data of yearly access, the study aims to enroll approximately: * 400 NDMM patients in a -36 months timeframe * 20 patients with monoclonal gammopathies in a -36 months timeframe * 50 RMM patients in a -36 months timeframe * 50 RRMM patients in a -36 months timeframe In addition, a retrospective cohort of patients will be included in this study after obtaining signed informed consent. This cohort will comprise no more than 25% of the total enrolled participants regardless of the phase of their disease. Patients will be selected based on the availability of existing residual biological material (samples collected not before January 2020), which will be analyzed as part of this study.
Cohort
Other
Not listed
Response assessment (according to IMWG criteria) and / or disease progression (PD)
Response to treatment <VGPR (according to IMWG criteria) and/or disease progression (PD)
Presence and/or absence of "secondary" tumor clone(s)
Presence and/or absence of differences between baseline characteristics and progression features
Click on the lead sponsor to view all of their trials.
